retatrutide type 2 diabetes phase 2 trial 🚨Breaking: Retatrutide's first 3 T2D data just dropped. ▸ A1C: −2.0% at 40 weeks ▸ Weight: −36.6 lbs (−16.8%) at 12 mg ▸ No weight loss plateau — curve still descending Looking forward to when #retatrutide's

Taspoglutide GLP-1 analogs can be effectively modified by incorporating alpha-aminoisobutyric acid (Aib) in place of Ala at the 8th position and Gly at the 35th position (Fig

Real-World Trends in GLP-1 Treatment Persistence and Prescribing for Weight Management

Youll see how one modest connection can spark multiple follow-ups when gravity pulls new symbols into place

It supports digestion, prevents dehydration from diarrhea episodes, and helps maintain regular bowel movements

Early Phase 2 clinical data, including results published in the New England Journal of Medicine in 2023, has shown considerable promise, with participants achieving substantial reductions in body weight

To date, liraglutide, and the more effective once-weekly semaglutide, have been approved in the US and Europe for the treatment of obesity, with unprecedented weight loss of up to 1520%